PAZOPANIB

26719 reported adverse events

Drug classes: Kinase Inhibitor [EPC]

These side effects are most commonly reported by patients taking PAZOPANIB:

# Side effect Count
0 MALIGNANT NEOPLASM PROGRESSION 497
1 PRODUCT USE IN UNAPPROVED INDICATION 340
2 DEATH 299
3 DIARRHOEA 299
4 FATIGUE 265
5 DISEASE PROGRESSION 243
6 DRUG INEFFECTIVE 242
7 NAUSEA 220
8 OFF LABEL USE 189
9 HYPERTENSION 183
See all common reactions for PAZOPANIB

PAZOPANIB is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 DESMOPLASTIC SMALL ROUND CELL TUMOUR 36 0.4138
1 ALVEOLAR SOFT PART SARCOMA METASTATIC 2 0.3333
2 EXTRASKELETAL MYXOID CHONDROSARCOMA 3 0.2727
3 SYNOVIAL SARCOMA METASTATIC 6 0.2500
4 CARDIAC VENTRICULAR SCARRING 3 0.2143
5 PLEOMORPHIC LIPOSARCOMA 2 0.2000
6 SOLITARY FIBROUS TUMOUR 3 0.1875
7 GRANULOCYTE-COLONY STIMULATING FACTOR LEVEL INCREASED 2 0.1667
8 OSTEOSARCOMA METASTATIC 15 0.1596
9 NEUROFIBROSARCOMA 13 0.1327
See all enriched reactions for PAZOPANIB